Seven Tumor Types: Pros and Cons

EP: 1.No Successor to OCM Would Disappoint

EP: 2.CMMI Open to Feedback, but EOM Out of the Blue

EP: 3.Some Practices That Did Not Do OCM Are Applying

Now Viewing

EP: 4.Seven Tumor Types: Pros and Cons

EP: 5.A Model That Is Built to “Win”

EP: 6.Addressing Health Equity and Social Needs

EP: 7.Is Five Years Long Enough?

EP: 8.Changes to MEOS and Barriers to Entry

EP: 9.Small Practices and Dual Risk: Considerations and Approaches

EP: 10.Does Pooling Make Sense?

EP: 11.What Would You Change About the EOM?

Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, led a discussion on a pros and cons of limiting the Enhancing Oncology Model (EOM) to 7 common cancer types. Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, and Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, agreed that honing in common cancers could lead to better predictability in cost of care. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance, raised concerns that lack of monthly payments for other cancer types for harm practices giving patients supportive services; Divers and Schleicher concurred on the potential effects on quality.